This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Archived

This page has been archived on the Web.

Health product recall

Co-Quetiapine 200 mg

Starting date:
May 18, 2013
Posting date:
June 4, 2013
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type I
Source of recall:
Health Canada
Issue:
Product Safety, Contamination
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-33889

Recalled products

  1. Co-Quetiapine 200 mg

Reason

Potential cross-contamination of trace amounts of Clindamycin in Quetiapine Active Pharmaceutical Ingredient during the manufacturing process.

Depth of distribution

Product distributed to wholesalers and pharmacies across Canada

Affected products

A. Co-Quetiapine 200 mg

DIN, NPN, DIN-HIM
DIN 02316110
Dosage form
  • Tablets
Strength
  • 200 mg / tablet
Lot or serial number

More than 10 numbers, contact manufacturer.

Companies
Recalling Firm
Cobalt Pharmaceuticals Inc.
6500 Kitimat Road,
Mississauga
L5N 2B8
Ontario
CANADA
Marketing Authorization Holder
Cobalt Pharmaceuticals Inc.
6500 Kitimat Road,
Mississauga
L5N 2B8
Ontario
CANADA

Date modified: